(2022). Efficacy and Safety and Mortality: Monitoring the patients on Rivaroxaban. test, 6(1), -. doi: 10.21608/cvrepj.2022.351464
. "Efficacy and Safety and Mortality: Monitoring the patients on Rivaroxaban". test, 6, 1, 2022, -. doi: 10.21608/cvrepj.2022.351464
(2022). 'Efficacy and Safety and Mortality: Monitoring the patients on Rivaroxaban', test, 6(1), pp. -. doi: 10.21608/cvrepj.2022.351464
Efficacy and Safety and Mortality: Monitoring the patients on Rivaroxaban. test, 2022; 6(1): -. doi: 10.21608/cvrepj.2022.351464

Efficacy and Safety and Mortality: Monitoring the patients on Rivaroxaban

Cardiovascular Research Prove Journal
Volume 6, Issue 1, June 2022    PDF (129.37 K)
Document Type: Abstracts
DOI: 10.21608/cvrepj.2022.351464
Abstract
No enough information available in matter of
patient on Rivaroxaban a direct factor Xa
inhibitor specially in Saudi population. In
addition, patient with chronic kidney disease,
valvular atrial fibrillation or liver disease must
not be considered for such therapeutic change.
This study will be the first to give an idea about
current practice being used at anticoagulant
clinic and criteria used to choose patients were
switched to Rivaroxaban
Statistics
Article View: 43
PDF Download: 57